AC Immune is a clinical-stage biopharmaceutical company emerging as a global leader in precision medicine to diagnose, treat and prevent neurodegenerative diseases.
Since AC Immune’s foundation in 2003, our staff has developed pioneering scientific and clinical expertise in the understanding and treatment of neurodegeneration. Our deep knowledge and cutting-edge technology platforms, SupraAntigen® and Morphomer®, are the engines for our diverse pipeline of clinical and preclinical product candidates.
Our experienced management team combines outstanding scientific, clinical, regulatory, financial and corporate development competencies to build on the seminal work of AC Immune’s founders.
The Board of Directors includes leading industry veterans, who oversee and optimize our corporate strategy and execution. We also benefit from working closely with collaboration partners, investors, clinicians and academic researchers.